BMY - Bristol-Myers Squibb Company
| Previous Close | 52.42 |
| Open | 52.45 |
| Bid | 53.00 x 900 |
| Ask | 53.02 x 1100 |
| Day's Range | 52.38 - 53.17 |
| 52 Week Range | 42.48 - 54.81 |
| Volume | 10,608,447 |
| Avg. Volume | 11,263,996 |
| Market Cap | 86.745B |
| Beta (3Y Monthly) | 0.58 |
| PE Ratio (TTM) | 13.97 |
| EPS (TTM) | 3.80 |
| Earnings Date | Oct 31, 2019 |
| Forward Dividend & Yield | 1.64 (3.18%) |
| Ex-Dividend Date | 2019-07-03 |
| 1y Target Est | 60.13 |
- GuruFocus.com
New Gilead CFO: Let's Make a Deal
The nearly $83 billion biotech giant seems poised to supercharge its M&A; and partnership efforts Continue reading...
- Zacks
Zacks.com featured highlights include: Hasbro, Atkore International, Target, Hibbett Sports and Bristol-Myers Squibb
Zacks.com featured highlights include: Hasbro, Atkore International, Target, Hibbett Sports and Bristol-Myers Squibb
- Zacks
Zacks.com featured highlights include: Lowe's, Bristol-Myers Squibb, AECOM and Vulcan Materials
Zacks.com featured highlights include: Lowe's, Bristol-Myers Squibb, AECOM and Vulcan Materials
- Business Wire
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
Bristol-Myers Squibb Company announced today the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the ...
- Barrons.com
4 Biotech Stocks That Are Set to Rally, Analyst Says
Bank of America Merrill Lynch’s Geoff Meacham sees the clouds lifting for the sector. He issued Buy ratings on four major names in the sector.
- MarketWatch
Fitbit stock gains after company announces biotech partnership
Fitbit Inc. shares are up 3.7% in premarket trading Thursday after the company announced a partnership with the Bristol-Myers Squibb-Pfizer Alliance focused on the detection of atrial fibrillation using Fitbit devices. As atrial fibrillation is a risk factor for stroke, the goal is to use technology to help patients detect this form of irregular heartbeat early on. Bristol-Myers Squibb Co. shares are up 0.4% premarket, while Pfizer Inc. shares are up 0.1%. Fitbit's stock has dropped 15% over the past three months as the S&P 500 has gained 0.2%.
- Zacks
The Extreme Risks of Trading Your Own Retirement Assets - October 17, 2019
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
- Yahoo Finance
Fitbit's plan to beat Apple in personal health
Fitbit is teaming up with Bristol-Myers Squibb and Pfizer in an effort to build out a new health care feature that could detect a heart condition in users.
- Zacks
5 High-Flying Stocks Near 52-Week High That Can Scale Higher
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
- Zacks
4 Stocks With Upgraded Broker Ratings to Buy Right Away
When brokers upgrade a stock, one can rely on their judgment. Nonetheless, one should also take into account some other factors to ensure steady returns.
- Zacks
Want To Retire Early? Learn the Intelligent Investing Secret - October 16, 2019
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
- GuruFocus.com
AbbVie, Bristol-Myers Squibb Getting the Most From Workers
Pharmaceutical companies that top the list in terms of sales per employee Continue reading...
- Zacks
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
FDA approves Johnson & Johnson's (JNJ) Xarelto to prevent blood clots in hospitalized acutely ill medical patients.
- Zacks
Bristol-Myers Squibb (BMY) Stock Moves -0.1%: What You Should Know
Bristol-Myers Squibb (BMY) closed at $51.56 in the latest trading session, marking a -0.1% move from the prior day.
- Zacks
Roche Announces Positive Late-Stage Data on Rituxan in PV
Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.
- Zacks
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
- Zacks
Is Bristol-Myers (BMY) a Solid Growth Stock? 3 Reasons to Think " Yes "
Bristol-Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.
- GuruFocus.com
6 Stocks Trading Below Peter Lynch Value
Bristol-Myers Squibb tops the list Continue reading...
- Insider Monkey
Were Hedge Funds Right About Betting On Bristol-Myers Squibb Company (BMY)?
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees during the first half of 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a […]
- Zacks
Clovis (CLVS) Shares Drop on Goldman Sachs' Bearish Outlook
Goldman Sachs lowers price target for Clovis' (CLVS) shares taking into account the risk of lower future revenues due to rising competition in the PARP inhibitor segment.
- Zacks
Nektar's Shares Drop on Rating Downgrade by Goldman Sachs
Nektar (NKTR) continues its downfall in 2019. Goldman Sachs downgrades the company's rating from Buy to Sell.
- Market Realist
Bristol-Myers Squibb: Could BMY Stock Surge Higher?
Is Bristol-Myers Squibb stock undervalued, and could it surge higher anytime soon? Find out why further upside is possible for BMY.
- Zacks
Signs That Your Trading Will Ruin Your Retirement - October 08, 2019
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
- Zacks
Infinity's (INFI) IPI-549 in Focus in a Crowded Cancer Space
Infinity (INFI) is currently focusing on the development of its lead immuno-oncology candidate IPI-549, an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma.
- Zacks
Why Alexion is a Hot Takeover Target in the Biotech Sector
Let's take a look at the factors, which make Alexion (ALXN) a hot target for a takeover amid the M&A wave in the pharma/biotech sector.
